SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                       Securities and Exchange Act of 1934



Date of Report (Date of earliest event reported)      JULY 31, 2003
                                                -----------------------


                         CALYPTE BIOMEDICAL CORPORATION.
              Exact name of Registrant as specified in its Charter)


                                    DELAWARE
                 (State or other jurisdiction of incorporation)


000-20985                                        06-1226727
---------                                        ----------
Commission File No.                    I.R.S. Employer Identification


1265 HARBOR BAY PARKWAY,
ALAMEDA, CA                                         94502
---------------------------------------             -----
Address of principal executive offices            Zip Code


(510) 749-5100
------------------------------
Registrant's telephone number,
including area code









ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c )     Exhibits.

         99.1     Calypte Biomedical Corporation earnings press release dated
                  July 31, 2003.

ITEM 9. REGULATION FD DISCLOSURE

In accordance with SEC Release No. 33-8126, the information contained herein and
in the accompanying exhibits is being furnished under both Item 9 and Item 12.

On July 31, 2003, the Registrant, ("Company") reported its fiscal second quartr
results for the period ended June 30, 2003. A copy of the press release issued
by the Company on July 31, 2003 concerning the foregoing results is furnished
herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this report, including the exhibit hereto, shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information contained herein and in the accompanying Exhibit shall not be
incorporated by reference into any filing with the U.S. Securities and Exchange
Commission made by the Company, whether made before or after the date hereof,
regardless of any incorporation language in such filing.

                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated:   Alameda, California
           August 4, 2003
                                           CALYPTE BIOMEDICAL CORPORATION
                                                    (Registrant)

                                           /s/ Richard D. Brounstein
                                           -----------------------------------
                                           Richard D. Brounstein
                                           Executive Vice President and Chief
                                           Financial Officer